Reuters
Published Mar 01, 2021 11:21PM ET
(Reuters) - The United States must stick to a two-dose strategy for the Pfizer-BioNTech and Moderna (NASDAQ:MRNA) COVID-19 vaccines, top U.S. infectious disease official Anthony Fauci told the Washington Post newspaper.
Fauci said that delaying a second dose to inoculate more Americans creates risks.
He warned that shifting to a single-dose strategy for the vaccines could leave people less protected, enable variants to spread and possibly boost skepticism among Americans already hesitant to get the shots.
"There's risks on either side," Fauci was quoted as saying by the Washington Post in a report published late on Monday.
"We're telling people (two shots) is what you should do … and then we say, 'Oops, we changed our mind'?" Fauci said. "I think that would be a messaging challenge, to say the least."
He added that he spoke with UK health officials on Monday who have opted to delay second doses to maximize giving more people shots more quickly. Fauci said that strategy would not make sense in the United States.
He said the science does not support delaying a second dose for those vaccines, citing research that a two-shot regimen creates enough protection to help fend off variants of the coronavirus that are more transmissible, whereas a single shot could leave Americans at risk from variants such as the one first detected in South Africa.
"You don't know how durable that protection is," he said.
Fauci said on Sunday he was encouraging Americans to accept any of the three available COVID-19 vaccines, including the newly approved Johnson & Johnson (NYSE:JNJ) shot.
The U.S. government authorized Johnson & Johnson's single-dose COVID-19 vaccine on Saturday, making it the third to be available in the country following the ones from Pfizer/BioNTech and Moderna that require two doses.
COVID-19 has claimed more than half a million lives in the United States, and states are clamoring for more doses to stem cases, hospitalizations and deaths.
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.